Across TCGA pan-cancer cohorts, IGKV6-21 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGKV6-21 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGKV6-21 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGKV6-21 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where IGKV6-21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.712	0.990	.001	37	view →
LSCC	DFS	Quartile	III,IV	0.195	0.841	.016	8	view →
PDAC	DFS	Median	IV	0.276	0.766	.047	3	view →
GBM	DFS	Median	All	0.509	0.296	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGKV6-21 tumor-vs-normal RNA expression · all IGKV6-21 data types